Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-cash Items: 2022-2025

Historic Non-cash Items for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $5.6 million.

  • Axsome Therapeutics' Non-cash Items rose 10.99% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year increase of 10.99%. This contributed to the annual value of $146.6 million for FY2024, which is 9.51% down from last year.
  • Per Axsome Therapeutics' latest filing, its Non-cash Items stood at $5.6 million for Q3 2025, which was down 95.85% from $133.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Non-cash Items registered a high of $300.7 million during Q4 2022, and its lowest value of $3.2 million during Q2 2022.
  • Its 3-year average for Non-cash Items is $100.2 million, with a median of $146.6 million in 2024.
  • As far as peak fluctuations go, Axsome Therapeutics' Non-cash Items surged by 4,942.72% in 2023, and later plummeted by 96.89% in 2024.
  • Over the past 4 years, Axsome Therapeutics' Non-cash Items (Quarterly) stood at $300.7 million in 2022, then crashed by 46.12% to $162.0 million in 2023, then declined by 9.51% to $146.6 million in 2024, then climbed by 10.99% to $5.6 million in 2025.
  • Its last three reported values are $5.6 million in Q3 2025, $133.8 million for Q2 2025, and $148.8 million during Q1 2025.